
Investors File Class Action Lawsuit Against ADMA Biologics
A securities fraud class action lawsuit now targets ADMA Biologics, accusing the company of inflating its stock value through deceptive financial reporting. The litigation claims that undisclosed related-party transactions and aggressive revenue-recognition tactics misled shareholders, resulting in significant market losses throughout the 2024 to 2026 class period.























